Efficacy of Ranolazine in reduction of blood sugar in type 2 diabetic patients with ischemic heart disease
- Conditions
- Condition 1: Diabetes mellitus. Condition 2: Stable angina.Type 2 diabetes mellitus with hyperosmolarityOther forms of angina pectoris
- Registration Number
- IRCT20161026030511N3
- Lead Sponsor
- Samin Daroo Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
HbA1c more than 6.5%, Age more than 50 year, both genders with diabetes mellitus and coronary artery disease (CAD)
Experiencing chronic stable angina for at least 3 months triggered by physical effort and relieved by rest and/or sublingual nitroglycerin
CAD documented by one or more of the following: Angiography evidence of more than 50% stenosis of one or more coronary arteries, History of MI, cardiac imaging or exercise test diagnostic for CAD
Treatment with up to 2 anti-anginal therapies at a stable dose for at least 2 weeks before starting the trial
T2DM patients who use Metformin and Gliclazide
New York Heart Association class III and IV
Acute coronary syndrome in the prior 2 months or planned for coronary revascularization
Stroke or transient ischemic attack within 6 months prior
QTc more than 500 ms
Systolic blood pressure more than 180, diastolic blood pressure more than 110 mmHg
Liver cirrhosis
Prior treatment with CYP 3A4 inhibitors or P GlyP inductors
Treatment with anti arrhythmic medicine class ll and lll
Alcohol consumption or drug users
Simvastatin consumption
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of HbA1c. Timepoint: Per month. Method of measurement: Blood test Hitachi 911 automatic analyzer.
- Secondary Outcome Measures
Name Time Method Reduction of using sublingual nitroglycerin per week. Timepoint: Weekly. Method of measurement: Patient report.